Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Should we be surprised at the paucity of response to EGFR inhibitors?

Gusterson BA, Hunter KD.

Lancet Oncol. 2009 May;10(5):522-7. doi: 10.1016/S1470-2045(09)70034-8. Review.

PMID:
19410197
2.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

3.

Structural basis for EGFR ligand sequestration by Argos.

Klein DE, Stayrook SE, Shi F, Narayan K, Lemmon MA.

Nature. 2008 Jun 26;453(7199):1271-5. doi: 10.1038/nature06978. Epub 2008 May 25.

4.

Cetuximab for the treatment of colorectal cancer.

Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ.

N Engl J Med. 2007 Nov 15;357(20):2040-8.

5.

The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1.

Jaalouk DE, Ozawa MG, Sun J, Lahdenranta J, Schlingemann RO, Pasqualini R, Arap W.

Cancer Res. 2007 Oct 15;67(20):9623-9.

6.

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis.

Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP.

Lancet Oncol. 2007 Oct;8(10):898-911. Epub 2007 Sep 20.

PMID:
17888735
7.

Ligand-induced structural transitions in ErbB receptor extracellular domains.

Dawson JP, Bu Z, Lemmon MA.

Structure. 2007 Aug;15(8):942-54.

8.

Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.

Binder M, Vögtle FN, Michelfelder S, Müller F, Illerhaus G, Sundararajan S, Mertelsmann R, Trepel M.

Cancer Res. 2007 Apr 15;67(8):3518-23.

9.

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6. Epub 2007 Feb 28. Erratum in: Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15965. Ritter, Gerd [added].

10.

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

Dassonville O, Bozec A, Fischel JL, Milano G.

Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. Epub 2007 Feb 26. Review.

PMID:
17324578
11.

Epidermal growth factor receptor mutations in lung cancer.

Sharma SV, Bell DW, Settleman J, Haber DA.

Nat Rev Cancer. 2007 Mar;7(3):169-81. Review.

PMID:
17318210
12.

Epidermal growth factor receptor targeting in cancer.

Mendelsohn J, Baselga J.

Semin Oncol. 2006 Aug;33(4):369-85. Review.

PMID:
16890793
13.

Targeting tyrosine kinases in cancer: the second wave.

Baselga J.

Science. 2006 May 26;312(5777):1175-8.

PMID:
16728632
14.

The epitope recognized by rituximab.

Binder M, Otto F, Mertelsmann R, Veelken H, Trepel M.

Blood. 2006 Sep 15;108(6):1975-8. Epub 2006 May 16.

15.

A hybrid vector for ligand-directed tumor targeting and molecular imaging.

Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini FC 3rd, Restel BH, Ozawa MG, Moya CA, Rangel R, Sun Y, Zaoui K, Schmidt M, von Kalle C, Weitzman MD, Gelovani JG, Pasqualini R, Arap W.

Cell. 2006 Apr 21;125(2):385-98.

16.

Cetuximab and radiotherapy for head and neck cancer.

Posner MR, Wirth LJ.

N Engl J Med. 2006 Feb 9;354(6):634-6. No abstract available.

PMID:
16467552
17.

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK.

N Engl J Med. 2006 Feb 9;354(6):567-78.

18.

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

Fujimoto N, Wislez M, Zhang J, Iwanaga K, Dackor J, Hanna AE, Kalyankrishna S, Cody DD, Price RE, Sato M, Shay JW, Minna JD, Peyton M, Tang X, Massarelli E, Herbst R, Threadgill DW, Wistuba II, Kurie JM.

Cancer Res. 2005 Dec 15;65(24):11478-85.

19.

Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.

Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E.

J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.

PMID:
16288119
20.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

Supplemental Content

Support Center